## STIMULANTS AND RELATED AGENTS PRIOR AUTHORIZATION FORM





(form effective 1/8/2024)

Fax to PerformRx<sup>SM</sup> at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774**.

PRIOR AUTHORIZ	ATION REQUEST	INFORMATION							
☐ New request ☐ Renewal request ☐ Total # of pages:									
Name of office contact:		Contact's phone number:			LTC fa	LTC facility contact/phone:			
PATIENT INFORM	ATION		1						
Patient name:				Patient ID #:			DOB:		
Street address:									
Apt #:	City/state/zip:				Phone:				
PRESCRIBER INFO	ORMATION								
Prescriber name:									
Specialty:			NPI:				State license #:		
Street address:									
Suite #:	City/state/zip:								
Phone:	I			Fax:					
CLINICAL INFORM	1ATION								
Drug requested:						Strength:			
Dosage form (tablet, ODT, suspension, etc.):						Quantity:		# months requested:	
Diagnosis (submit documentation):						Diagnosis co	iagnosis code (required):		
INITIAL REQUEST	S				-				
							Submit d	documentation	
						□ No	□ No		
For a non-preferred drug: Does the beneficiary have a history of trial and failure of or contraindication or intolerance to						□ Yes	les List preferred medications tried:		
the preferred drugs in this class that are approved or medically accepted for treatment of the beneficiary's condition?  Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred drugs in this class.					□ No	□ No			
Complete the sections below that are applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.    For an analeptic Stimulants and Related Agents (e.g., Provigil, Nuvigil, Sunosi, Wakix)   Is not receiving concurrent treatment with sedative/hypnotic medications   Is receiving concurrent treatment with sedative/hypnotic medications — reason:   For the treatment of narcolepsy:   Has a diagnosis of narcolepsy that is consistent with current International Classification of Sleep Disorders criteria (e.g., MSLT, overnight PSG, hypocretin-1 concentration, clinical assessment, etc.)   For the treatment of shift work sleep disorder:   Has a diagnosis of shift work sleep disorder that is consistent with current International Classification of Sleep Disorders criteria (e.g., shift work schedule, sleep log and actigraphy monitoring, other causes ruled out, clinical assessment, etc.)   For the treatment of obstructive sleep apnea/hypopnea syndrome (OSAHS):   Has a diagnosis of OSAHS that is consistent with current International Classification of Sleep Disorders criteria (e.g., overnight PSG, out-of-center sleep testing, associated medical or psychiatric disorders, clinical assessment, etc.)   Tried and failed continuous positive airway pressure (CPAP) while adherent to treatment to resolve daytime sleepiness demonstrated by:   Epworth Sleepiness Scale > 10   Multiple sleep latency test (MSLT) < 8 minutes   Cannot use CPAP — reason:   Tried and failed an oral appliance for OSAHS to resolve daytime sleepiness									
☐ For the treatment of ☐ Is currently receivi ☐ Is not receiving tre ☐ For a child <4 years of	fatigue related to multip ng treatment for MS atment for MS — reason of age: equested medication ANE plogist nt psychiatrist					g specialists	:		



INITIAL REQUESTS (continued)								
☐ For a beneficiary ≥18 years of age: ☐ For the treatment of ADHD:								
☐ Has a diagnosis of ADHD that is consistent with current DSM criteria								
☐ For the treatment of narcolepsy:								
☐ Has a diagnosis of narcolepsy consistent with current International Classification of Sleep Disorders criteria								
(e.g., MSLT, overnight PSG, CSF hypocretin-1 concentration, clinical assessment)								
☐ For the treatment of binge eating disorder:								
☐ Has a diagnosis of moderate to severe binge eating disorder that is consistent with the current DSM criteria								
☐ Tried and failed (or cannot try) SSRIs (unless beneficiary has comorbid ADD or ADHD)								
☐ Tried and failed (or cannot try) topiramate (unless beneficiary has comorbid ADD or ADHD)								
☐ Was referred for cognitive behavioral therapy or other psychotherapy								
☐ For a stimulant agent:								
☐ Was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history								
☐ Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction								
☐ Has documentation that the provider checked the PDMP for the beneficiary's controlled substance prescription history								
☐ For a beneficiary with a history of substance dependency, abuse, or diversion:								
☐ Has results of a recent UDS for licit and illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol)								
that is consistent with prescribed controlled substances								
DENEWAL PROJECTS								
RENEWAL REQUESTS								
Has the beneficiary experienced a positive clinical response since starting the requested medication?	☐ Yes	Submit documentation						
	□ No							
	□ INU							
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION								
Prescriber signature:		Date:						

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

ACPA\_233159900-9 Coverage by AmeriHealth First.